Meir J Stampfer

Title: Meir J Stampfer: Innovator in Prostate Cancer Research

Introduction

Meir J Stampfer is a prominent inventor based in Brookline, MA (US). He has made significant contributions to the field of prostate cancer research, holding 2 patents that focus on methods for predicting and monitoring prostate cancer risk.

Latest Patents

Stampfer's latest patents include innovative methods for predicting a propensity to develop prostate cancer. These methods involve measuring the insulin-like growth factor (IGF) status of individuals. Research indicates that individuals with high IGF status, compared to normal reference range values, are at an increased risk for developing prostate cancer. Specifically, the IGF status can be determined by measuring IGF-I levels and/or insulin-like growth factor binding protein-3 (IGFBP-3) levels. High IGF and low IGFBP levels are indicative of a high IGF status. Furthermore, a method for determining the prognosis of existing prostate cancers or monitoring disease progression involves assessing the IGF/PSA status of an individual. Those with a high IGF/PSA status, characterized by both high IGF and high PSA levels, tend to develop severe prostate cancer and have a poorer overall prognosis.

Career Highlights

Throughout his career, Meir J Stampfer has focused on advancing the understanding of prostate cancer and its risk factors. His research has contributed to the development of predictive methods that can aid in early detection and treatment strategies.

Collaborations

Stampfer has collaborated with notable colleagues in the field, including Michael N Pollak and Edward Giovannucci. These partnerships have further enhanced the impact of his research on prostate cancer.

Conclusion

Meir J Stampfer's work in prostate cancer research exemplifies the importance of innovation in medical science. His patents and research efforts continue to contribute to the understanding and management of prostate cancer risk.